EGFR (Epidermal Growth Factor Receptor) signaling and the mitochondria regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) secretion

R Hastie; FC Brownfoot; N Pritchard; NJ Hannan; P Cannon; V Nguyen; K Palmer; S Beard; S Tong; TJ Kaitu'U-Lino

Journal article

EGFR (Epidermal Growth Factor Receptor) signaling and the mitochondria regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) secretion

R Hastie, FC Brownfoot, N Pritchard, NJ Hannan, P Cannon, V Nguyen, K Palmer, S Beard, S Tong, TJ Kaitu'U-Lino

Hypertension | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019

DOI: 10.1161/HYPERTENSIONAHA.118.12300

Abstract

Preeclampsia is a hypertensive disorder of pregnancy characterized by maternal endothelial dysfunction and end-organ damage. The antiangiogenic factor, sFlt-1 (soluble FMS-like tyrosine kinase-1) has been strongly implicated in the pathogenesis of preeclampsia. sFlt-1 is secreted into the maternal circulation where it antagonizes VEGF (vascular endothelial growth factor) and ultimately disrupts vascular homeostasis. However, the upstream mechanisms regulating release of sFlt-1 are poorly characterized. We investigated the roles of key prosurvival pathways, EGFR (epidermal growth factor receptor) signaling, and the mitochondria, in regulating sFlt-1 production. We initially found that the mRN..

View full abstract

University of Melbourne Researchers

A/Prof Roxanne Hastie Author

A/Prof Fiona Brownfoot Author

Dr Natasha Pritchard Author

Prof Natalie Hannan Author

Related Projects (5)

TARGETING THE TOXINS OF PREECLAMPSIA

Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her ..

BENCH TO BESIDE TRANSLATIONAL STUDIES TO DEVELOP TREATMENTS FOR PREECLAMPSIA

Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medica..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

FROM PATHOGENESIS TO THERAPEUTICS: TARGETING TWO SIGNALLING PATHWAYS AS A THERAPEUTIC STRATEGY TO TREAT PREECLAMPSIA

Preeclampsia is a serious complication of pregnancy that claims the lives of thousands of mothers and babies each year. There is no efficaci..

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by the National Health and Medical Research Council (National Health and Medical Research Council [NHMRC] of Australia (No. 1126710). R. Hastie was supported via an Australian Postgraduate Award scholarship. S Tong (No. 1136418), T.J. Kaitu'u-Lino (No. 1062418), N.J. Hannan (No. 1146128), and F.C. Brownfoot (No. 1142636) were supported by NHMRC Fellowships. The funders had no role in study design, data collection, analysis, decision to publish, or the preparation of the article.